产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0575-1.jpg)
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0575-2.jpg)
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0575-3.jpg)
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0575-4.jpg)
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0575-5.jpg)
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0575-6.jpg)
![B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确)](/Public/upfile/pic/product/cell-line-new.jpg)
产品概述
| 名称 | B-CPAP [BC-PAP; BCPAP] (人甲状腺乳头状癌细胞) (STR鉴定正确) |
| 别称 | BC-PAP; BCPAP |
| 种属 | 人 |
| 生长特性 | 贴壁细胞 |
| 细胞形态 | 圆形/长梭形 |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养方案A（默认） |
培养条件:
气相：空气，95%；CO2，5%, 温度：37℃
|
| 推荐传代比例 | 1:3-1:5 |
| 推荐换液频率 | 2-3次/周 |
| 背景描述 | Established from the tumor tissue of a 76-year-old woman with metastasizing papillary thyroid carcinoma in 1992 |
| 年龄（性别） | 女性；76岁 |
| 组织来源 | 甲状腺组织 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 其它肿瘤细胞 |
| 生物安全等级 | BSL-1 |
| 倍增时间 | ~30 hours |
| 保藏机构 | DSMZ; ACC-273 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 13 D2S1338 18 D3S1358 16,17 D5S818 10,11 D7S820 10 D8S1179 12,13 D13S317 12 D16S539 11,12 D18S51 13,17 D19S433 13.2,15 D21S11 30,31.2 FGA 20,23 PentaD 10,11 PentaE 5,12 TH01 6,9.3 TPOX 8,11 vWA 14,17 D6S1043 12,19 D12S391 18,23 D2S441 11 -
STR鉴定图
-
参考文献
-
Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission(2024/02/09)
作者：Yawen Guo, Lei Zhu, Yanting Duan
期刊：Cell Death & Disease
DOI：10.1038/s41419-024-06511-1
影响因子 ：9.000
引用产品：CL-0575
-
RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex(2023/02/21)
作者：Xu Debin, Yu Jichun, Yang Yuting, Du Yunyan, Lu Hongcheng, Zhang Shouhua, Feng Qian, Yu Yi, Hao Liang, Shao Jun, Chen Leifeng
期刊：Cell and Bioscience
DOI：10.1186/s13578-023-00987-8
影响因子 ：7.500
引用产品：CL-0575 CL-0617 CL-0618 CL-0624 CL-0643 CL-0648 CL-0649
-
Long non-coding RNA ACTA2-AS1 suppresses metastasis of papillary thyroid cancer via regulation of miR-4428/KLF9 axis(2024/01/09)
作者：Shuhui Wu, Jingjing Zhu, Tingting Jiang
期刊：Clinical Epigenetics
DOI：10.1186/s13148-023-01622-6
影响因子 ：5.700
引用产品：CL-0575
-
AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling(2024/01/18)
作者：Gaoda Ju, Tao Xing, Miaomiao Xu
期刊：NEOPLASIA
影响因子 ：4.800
引用产品：CL-0575
-
FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis(2023/07/26)
作者：Gaoxiang Chen, Jianan Zhang, Weifeng Teng
期刊：Heliyon
DOI：10.1016/j.heliyon.2023.e18655
影响因子 ：4.000
引用产品：CL-0575
-
DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression(2024/01/17)
作者：Zanbin Li, Yong Ying, Xiangtai Zeng
期刊：FUNCTIONAL & INTEGRATIVE GENOMICS
DOI：10.1007/s10142-024-01293-3
影响因子 ：2.900
引用产品：CL-0575
-
FOXA2 suppresses PKM2 transcription and affects the Wnt/β-catenin activity to block aerobic glycolysis in thyroid carcinoma(2023/03/22)
作者：Yawei He, Wanjing Chen, Liang Yu
期刊：CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
影响因子 ：2.900
-
The Antitumour Effect of Prunella vulgaris Extract on Thyroid Cancer Cells In Vitro and In Vivo(2021/01/09)
作者：Fangqin Yu, Lele Zhang, Runsheng Ma
期刊：Evidence-Based Complementary and Alternative Medicine
影响因子 ：2.650
-
High Expression of BHLHE40 Promotes Immune Infiltration and Tumor Progression in Thyroid Cancer(2023/03/28)
作者：Qilin Gong, Huaying Li
期刊：CHINESE JOURNAL OF PHYSIOLOGY
DOI：10.4103/cjop.CJOP-D-22-00076
影响因子 ：1.800
引用产品：CL-0575
-
New insights into COL26A1 in thyroid carcinoma: prognostic prediction, functional characterization, immunological drug target and ceRNA network(2023/12/27)
作者：Yulou Luo, Yinghui Ye, Yuting Zhang
期刊：Translational Cancer Research
影响因子 ：0.900
引用产品：CL-0575
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
